Abstract
Essential hypertension is a major factor for myocardial infarction, heart failure and kidney failure. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and vasodilatation directly or indirectly with other hormones and humoral factors, such as reactive oxygen species and the renin-angiotensin system. Dopamine receptors are classified into five subtypes based on their structure and pharmacology. Among those dopamine receptor subtypes, D1 receptor is the most important one, during conditions of moderate sodium intake, more than 50% of renal sodium excretion is regulated by D1-like receptors. Decreased renal dopamine production and/or impaired D1 receptor function have been reported in hypertension. Disruption of D1 receptor results in hypertension. In this paper, we review the mechanisms by which hypertension develops when D1 receptor function is perturbed. We also discuss possible new approaches developing anti-hypertensive medicine by increasing renal dopamine production, enhancing D1 receptor function, or modifying its interactions with other blood pressure-regulating systems.
Keywords: Essential hypertension, D1 dopamine receptor, G protein-coupled receptor kinase type 4, protein phosphotase 2A, endocytosis, desensitization, sodium excretion, vasorelaxation
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: A New Approach for Treatment of Hypertension: Modifying D1 Dopamine Receptor Function
Volume: 4 Issue: 4
Author(s): Chunyu Zeng, Robin A. Felder and Pedro A. Jose
Affiliation:
Keywords: Essential hypertension, D1 dopamine receptor, G protein-coupled receptor kinase type 4, protein phosphotase 2A, endocytosis, desensitization, sodium excretion, vasorelaxation
Abstract: Essential hypertension is a major factor for myocardial infarction, heart failure and kidney failure. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and vasodilatation directly or indirectly with other hormones and humoral factors, such as reactive oxygen species and the renin-angiotensin system. Dopamine receptors are classified into five subtypes based on their structure and pharmacology. Among those dopamine receptor subtypes, D1 receptor is the most important one, during conditions of moderate sodium intake, more than 50% of renal sodium excretion is regulated by D1-like receptors. Decreased renal dopamine production and/or impaired D1 receptor function have been reported in hypertension. Disruption of D1 receptor results in hypertension. In this paper, we review the mechanisms by which hypertension develops when D1 receptor function is perturbed. We also discuss possible new approaches developing anti-hypertensive medicine by increasing renal dopamine production, enhancing D1 receptor function, or modifying its interactions with other blood pressure-regulating systems.
Export Options
About this article
Cite this article as:
Zeng Chunyu, Felder A. Robin and Jose A. Pedro, A New Approach for Treatment of Hypertension: Modifying D1 Dopamine Receptor Function, Cardiovascular & Hematological Agents in Medicinal Chemistry 2006; 4 (4) . https://dx.doi.org/10.2174/187152506778520727
DOI https://dx.doi.org/10.2174/187152506778520727 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets TRPC3-Based Protein Signaling Complex as a Therapeutic Target of Myocardial Atrophy
Current Molecular Pharmacology Effects of Oral L-Citrulline Supplementation on Lipoprotein Oxidation and Endothelial Dysfunction in Humans with Vasospastic Angina
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Biotechnological Methods to Reduce Oxidative Stress in the Cardiovascular System: Focusing on the Bach1/Heme Oxygenase-1 Pathway
Current Pharmaceutical Biotechnology Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics Resistant Hypertension: Novel Insights
Current Hypertension Reviews Aliskiren: A New Drug for an Old Problem
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Design, Synthesis, and Bioactivity of Pyrazole Acid Derivatives as Endothelin Receptor Antagonists
Medicinal Chemistry Real-Time Location, Position and Motion Data for Healthcare Information Systems – A Patent Review
Recent Advances in Communications and Networking Technology (Discontinued) The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries
Current Vascular Pharmacology Cardiovascular Effects of Omega-3 Free Fatty Acids.
Current Vascular Pharmacology